worldwide offices | stay connected | contact | help | sitemap

 
 

 

 

 

Novartis Investor Relations

Novartis Investor Relations

Pharmaceutical product overview

 
Indication Product Full year 2008 sales
Click here for further information Click on product name for further information USD m variance in USD
Alzheimer's disease
Exelon
815
29%
Parkinson's disease
Comtan
502
20%
Epilepsy
Tegretol
451
9%
Attention deficit disorder
Ritalin
focalin
440
17%
Epilepsy
Trileptal
332
-52%
Indication Product Full year 2008 sales
Click here for further information Click on product name for further information USD m variance in USD
Hypertension
Diovan
Co-Diovan
5740
15%
Cholesterol reduction
Lescol
645
-3%
Hypertension
Exforge
406
294%
Hypertension
Lotrel
386
-48%
Indication Product Full year 2008 sales
Click here for further information Click on product name for further information USD m variance in USD
Asthma
Foradil
387
7%
Cystic Fibrosis
Tobi
295
8%
Indication Product Full year 2008 sales
Click here for further information Click on product name for further information USD m variance in USD
Transplantation
Sandimmum/Neoral
956
1%
Transplantation
Myfortic
290
50%
Indication Product Full year 2008 sales
Click here for further information Click on product name for further information USD m variance in USD
Chronic myeloid leukemia
Glivec
3670
20%
Cancer complications
Zometa
1382
7%
Breast cancer
Femara
1129
20%
Acromegaly
Sandostatin
1123
9%
Iron chelator
Exjade
531
49%
Indication Product Full year 2008 sales
Click here for further information Click on product name for further information USD m variance in USD
Inflammation / pain
Voltaren
814
9%
Indication Product Full year 2008 sales
Click here for further information Click on product name for further information USD m variance in USD
Age-related macular degeneration
Lucentis
886
125%

Quarterly results

View and download the latest quarterly reports from Novartis.

Corporate publications

Corporate publications

Download our latest financial reports.

Latest news